News for Abeona Therapeutics Inc Registered Shs

Seeking Alpha 39d

ABEO, KPRX and RGTI among pre market losers

Benzinga 118d

PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week

InvestorPlace 118d

PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week

TipRanks 125d

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Abeona Therapeutics (ABEO)

Seeking Alpha 126d

Abeona Therapeutics GAAP EPS of -$1.48

GlobeNewswire 126d

Abeona Therapeutics Reports Third Quarter 2022 Financial Results

Benzinga 131d

Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'

TipRanks 133d

Abeona Therapeutics (ABEO) Gets a Hold from SVB Securities

Seeking Alpha 137d

Abeona says phase 3 trial of EB-101 cell therapy for rare skin disorder meets main goals

Seeking Alpha 137d

CLSD, TSHA and CLNN are among pre market gainers

GlobeNewswire 137d

Abeona Therapeutics Announces $35 Million Private Placement Financing

GlobeNewswire 137d

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

Seeking Alpha 137d

Abeona Therapeutics announces $35M private placement

GlobeNewswire 152d

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Seeking Alpha 153d

Akouos, AVEO lead healthcare gainers; Salarius, RVL among losers

Benzinga 154d

Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday

Seeking Alpha 158d

ABEO, RLX and SSTI among mid-day movers

Benzinga 161d

Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday

Benzinga 163d

Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session

Seeking Alpha 163d

CGC, ABEO and NVIV among premarket gainers

Seeking Alpha 166d

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

GlobeNewswire 167d

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Seeking Alpha 167d

Cantor lists three “high conviction” Phase 3 biotech readouts for Q4

Seeking Alpha 174d

Avenue, Equillium top healthcare gainers; Avidity, Kiora lead losers' pack

GlobeNewswire 179d

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

GlobeNewswire 188d

Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference

GlobeNewswire 221d

Abeona Therapeutics Reports Second Quarter 2022 Financial Results

Seeking Alpha 221d

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Seeking Alpha 228d

SENS, YELL and ABEO are among pre market gainers

GlobeNewswire 243d

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

Seeking Alpha 243d

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement